Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter open-label multiple-dose study of UCB7665 in primary immune thrombocytopenia
2015-003984-12Phase 2Completed
- Sponsor
- UCB
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rozanolixizumab in immune thrombocytopenia (ITP), sponsored by UCB. Primary endpoint: Treatment-emergent adverse events. Started Nov 2015; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2015-003984-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003984-12.